SVRA logo

Savara Inc. Stock Price

NasdaqGS:SVRA Community·US$1.6b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

SVRA Share Price Performance

US$6.45
3.37 (109.42%)
US$6.45
3.37 (109.42%)
Price US$6.45

SVRA Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

2 Risks
1 Reward

Savara Inc. Key Details

US$0

Revenue

US$83.8m

Cost of Revenue

-US$83.8m

Gross Profit

US$31.8m

Other Expenses

-US$115.6m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.48
0%
0%
31.6%
View Full Analysis

About SVRA

Founded
2007
Employees
59
CEO
Matthew Pauls
WebsiteView website
www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Recent SVRA News & Updates

Recent updates

No updates